



US00655532B1

(12) **United States Patent**
Smart et al.

(10) **Patent No.:** **US 6,555,532 B1**
(45) **Date of Patent:** ***Apr. 29, 2003**

(54) **METHOD OF TREATING ALOPECIA**

(75) Inventors: **Robert C. Smart**, Raleigh, NC (US);
Hye-Sun Oh, Raleigh, NC (US)

(73) Assignee: **North Carolina State University**,
Raleigh, NC (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **09/697,214**

(22) Filed: **Oct. 26, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/257,396, filed on Feb.
25, 1999, now Pat. No. 6,204,258, which is a continuation
of application No. 08/604,448, filed on Feb. 21, 1996, now
Pat. No. 5,965,551.

(51) **Int. Cl.**⁷ **A61K 31/56**

(52) **U.S. Cl.** **514/182; 514/324; 514/422;**
514/651; 514/880

(58) **Field of Search** 514/182, 324,
514/422, 651

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,139,619	A	2/1979	Chidsey, III	424/45
4,596,812	A	6/1986	Chidsey, III et al.	514/256
4,828,837	A	5/1989	Uster et al.	424/450
5,026,691	A	6/1991	Kligman	514/171
5,068,315	A	11/1991	Buultjens et al.	530/324
5,177,061	A	1/1993	Pickart	514/18
5,183,814	A *	2/1993	Dukes	514/171
5,225,189	A	7/1993	Pena	424/70
5,358,714	A	10/1994	Green	424/400
5,395,842	A	3/1995	Labrie et al.	514/320
5,407,944	A	4/1995	Goldman	514/310
5,574,048	A	11/1996	Cullinan	514/324
5,643,942	A	7/1997	Hester, Jr. et al.	514/456

FOREIGN PATENT DOCUMENTS

EP	659414	6/1995
WO	96/01099	1/1996

OTHER PUBLICATIONS

A.E. Wakeling et al.; A Potent Specific Antiestrogen with
Clinical Potential, *Cancer Res.* 51:3867-3873 (1991).

J. Bowler et al.; Novel Steroidal Pure Antiestrogens, *ICI
Pharmaceuticals, Research Dept.* (1988).

H. Jiang et al.; Induction of Anagen in Telogen Mouse Skin
by Topical Application of FK506, a Potent Immunosuppres-
sant, *J. of Invest. Derm.* 104:523-525 (1995).

J.P. Jacobs et al.; Use of Topical Minoxidil Therapy for
Androgenetic Alopecia in Women, *Int'l J. of Derm.*
32:758-762 (1993).

D.H. Rushton; Management of Hair Loss in Women, *Derm.
Therapy* 11 No. 1:47-53 (1993).

G. Bazzano et al.; Effect of Retinoids on Follicular Cells, *J.
of Invest. Derm.*, 101 No. 1 (Supp):138S-142S (1993).

H. Uno et al.; Chemical Agents and Peptides Affect Hair
Growth, *J. of Invest. Derm.* 101 No. 1 (Supp) 138S-142S
(1993).

W.S. Branham et al.; ICI 182,780 Inhibits Endogenous
Estrogen-Dependent Rat Uterine Growth and Tamoxifen-
Induced Development Toxicity, *Bio of Reproduct*
54:160-167 (1996).

C. Levesque et al.; Synthesis and Biological Activity of New
Halo-Steroidal Antiestrogens, *J. Med. Chem.* 34:1624-1630
(1991).

A. Claussner et al.; 11 β -Amidoalkyl Estradiols, A New
Series of Pure Antiestrogens, *J. Steroid Biochem. Molec.
Biol.* 41 No. 3-8:609-614 (1992).

D. Poirier et al.; Synthesis and Antiestrogenic Activity of
Diaryl Thioether Derivatives, *J. Med. Chem.* 37:1115-1125
(1994).

V.C. Jordan; Hydroxylated Antioestrogens: New Pharmaco-
logical Probes to Investigate Oestrogen and Antioestrogen
Action, *Hormone Antagonists* 110-111 (1982).

J. Rosen et al.; Intracellular Receptors and Signal Transduc-
ers and Activators of Transcription Superfamilies: Novel
Targets for Small-Molecule Drug Discovery, *J. Med. Chem.*
38 No. 25:4855-4874 (1995).

Archer, C.B., et al., *Alopecia neoplastica responsive to
tamoxifen; The Royal Society of Medicine*, vol. 83, No. 10,
pp. 647-648 (1990).

* cited by examiner

Primary Examiner—Rebecca Cook

(74) *Attorney, Agent, or Firm*—Myers Bigel Sibley &
Sajovec

(57) **ABSTRACT**

A method of enhancing hair growth or treating alopecia in a
subject uses topically administered estrogen receptor
antagonists. Pharmaceutical formulations comprising estrogen
receptor antagonists are described.

12 Claims, 15 Drawing Sheets